Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ardelyx, Inc. - Common Stock
(NQ:
ARDX
)
4.180
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ardelyx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
May 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
May 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
May 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Earnings Scheduled For May 1, 2025
May 01, 2025
Via
Benzinga
Breaking Down Ardelyx: 4 Analysts Share Their Views
February 21, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
What Analysts Are Saying About Ardelyx Stock
January 27, 2025
Via
Benzinga
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
May 06, 2025
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress
From
Ardelyx, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
May 02, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 02, 2025
Via
Benzinga
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 02, 2025
Via
Benzinga
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
May 02, 2025
Via
Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
May 01, 2025
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
May 01, 2025
Via
Benzinga
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
May 01, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
April 29, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
April 24, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
April 17, 2025
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
April 10, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
March 31, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
March 13, 2025
Award established to recognize leaders in the field of chronic kidney disease advocacy
From
Ardelyx, Inc.
Via
GlobeNewswire
Tenapanor Approved in China for Hyperphosphatemia
February 26, 2025
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Participate in Upcoming Investor Conferences
February 25, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism
February 20, 2025
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.
Via
Stocktwits
Ardelyx Tops Estimates as Sales Surge
February 20, 2025
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.
Via
The Motley Fool
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?
February 20, 2025
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session.
Via
Benzinga
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 20, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
February 19, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
January 30, 2025
Conference call scheduled for 8:00 a.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
January 13, 2025
From
Ardelyx, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.